Organisation paid for research Program year 2025 Source: CMS Open Payments

Complete Dermatology

Neither a doctor nor a teaching hospital

Research payments

$375,712

66 payments

Through program year 2025, Complete Dermatology is reported as receiving $375,712 in research payments, across 66 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $75,475 24
2024 Research $141,655 25
2023 Research $115,281 14
2022 Research $14,027 2
2021 Research $29,273 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $264,012 21 payments
  2. Pfizer Inc. $95,211 32 payments
  3. Incyte Corporation $16,488 13 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $76,773 23 payments
  2. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $58,213 2 payments
  3. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $50,248 3 payments
  4. An Open-Label 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $41,215 2 payments
  5. An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $29,724 2 payments
  6. An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $27,352 3 payments
  7. An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $23,251 4 payments
  8. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $18,438 9 payments
  9. The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $16,488 13 payments
  10. Psosa (Psoriasis Special Areas) - A US-Based Single-Arm Prospective Multicenter Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated With Ixekizumab $13,827 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record